09 Aug 06
The protection of intellectual property (IP) rights has become crucial to the success of many foreign investors and enterprises who wish to profit from China‚Äôs fast growing market. As many foreign investors have discovered that counterfeiting, passing off and other forms of IP infringement are common in China. At the same time, Chinese companies are investing heavily in sophisticated technology and require an effective IP system to protect their own investment.
The dynamics of protecting inte
08 Aug 06
Andy Sarfas is our mover and shaker of the week. He is the Global Internet Business Manager for Reckitt Benckiser.
08 Aug 06
David Mitchell is the Commercial Director at McNeil Consumer Healthcare, a company that produces remedies for self-treatment available at pharmacies and supermarket stores.
08 Aug 06
Alex Bishop is the IT Business Manager at Pfizer, the largest supplier of medicines to the NHS.
04 Aug 06
Because of the ever-increasing costs of healthcare provision the world over, many governments are enacting legislation to promote generic prescription in order to keep costs down. With drugs worth $160 billion in sales coming off patent by 2015, it would seem a good time to be in the generics industry. However the generics market is not without challenges.
03 Aug 06
Manufacturing Instructions and Records: Operators are expected to follow manufacturing instructions to produce a product that meets the required specification. Typically these instructions will be written by technical experts, the chemical engineers who were responsible for the technology transfer, the process validation and so on.
PharmiWeb.com Field Reporter: Joanna Hills
02 Aug 06
Every sponsor or CRO can expect their country‚Äôs regulatory agency to arrive on their premises periodically to conduct routine inspections. In the UK, for instance, the Medicines and Healthcare products Regulatory Agency (MHRA) conducts routine periodic inspections approximately every three years. Apart from these, the MHRA also conducts ‚Äúfor cause‚ÄĚ and ‚Äúfollow up‚ÄĚ inspections, and they also take part in the third-country inspection program. Because all inspections may be either announced or unan
01 Aug 06
Doctors taking part in a survey on Alzheimer‚Äôs Disease (AD) management have called for clear and consistent guidelines on diagnosis and treatment of the condition to be drawn up as a matter of urgency. The survey was sponsored by Eisai Europe Ltd and Pfizer Inc, who market the cholinesterase inhibitor Aricept (donepezil), and was presented during the International Conference on Alzheimer‚Äôs Disease and Related Disorders.
Olwen Glynn Owen ‚Äď Pharmiweb Field Reporter
31 Jul 06
The Treasury is aware of a growing trend, which has recently moved into the pharmaceutical sector, for staff to be provided to clients through ‚Äúumbrella‚ÄĚ or ‚Äúcomposite‚ÄĚ companies. These companies promise a golden scenario of reduced costs to their clients and greater take-home pay to the individuals who work through them.
31 Jul 06
Atrial fibrillation (AF) is the most common form of arrhythmia, or irregular heartbeat, with an estimated nine million sufferers worldwide. Although safe, effective treatment for AF is critical, historically there has been little R&D investment and little innovation in the AF market. However, this may be about to change, with the AF market expected to triple by 2015.
25 Jul 06
Cognitive behaviour therapy (CBT) combines two very effective kinds of psychotherapy delivered face to face by medical therapists
Jim Melling - PharmiWeb Field Reporter
25 Jul 06
In the last report we analysed part of an SOP control system for inefficiencies and opportunities for error, by mapping the system and asking ‚Äėwhat if?‚Äô at each stage. But, as we mentioned previously, documentation systems (or, indeed, any type of control system) rarely operate in isolation. So let‚Äôs look at some of the inputs and outputs there might be on a typical site, using the same process as before.
Joanna Hills - PharmiWeb Field Reporter
21 Jul 06
PowderMed has submitted an application to UK regulators seeking to conduct human trials of its avian influenza vaccine. Developing an effective vaccine against the next influenza pandemic is a challenging task, but one many companies are taking on. However, until a virus able to cause a pandemic emerges, no one knows for certain which product will be most effective.
20 Jul 06
Treatment of chronic kidney disease (CKD) is focussing increasingly on prevention of cardiovascular complications with the aim of reducing the cardiovascular mortality and morbidity to which many patients currently succumb.
Olwen Glynn Owen - PharmiWeb Field Reporter
19 Jul 06
Hints and Tips: Survive in the Work Place Part Two
Elaine Ford - PharmiWeb Field Reporter
13 Jul 06
'Drug In Focus' is written by Leighton Howard, a patent information expert with extensive generics experience. He has worked within the professional patent information industry and major generic pharmaceutical firms and now provides consultancy services to the generics industry and government organisations via his company XIP Pty Ltd. He is also the founder of GenericsWeb and remains instrumental in maintaining the high quality and accuracy of data contained in Pipeline Patent Intelligence.
13 Jul 06
Despite not being a widely acknowledged affliction, urinary incontinence (UI) is a relatively common condition, with up to 23% of the female population suffering from one form alone. Yet despite the significant impact UI can have on the quality of life of the sufferers, according to a new report, approximately half of sufferers neither seek treatment nor report the problem to a physician.
10 Jul 06
ROCHE is set to file for a new indication for its oral, targeted cancer drug Xeloda¬ģ following impressive new data presented at the American Society of Clinical Oncology conference (ASCO).
09 Jul 06
Pharmaceutical companies are renowned for exhaustive pages of regulatory reports and documentation procedures. An enormous amount of effort goes into creating and maintaining these documentations, usually by people for whom it is only a small part of their job.
Another problem is that complexity exists in such documents and may be due to an excess of information or to inappropriate structure. Again, historically there may have been a drive to put every little detail into the procedures, in t
PharmiWeb Field Reporter -Joanna Hills
07 Jul 06
Todays Headlines from across the DailyUpdates network (July 7th, 2006) - In today's edition we highlight Biomarin's development of the novel antihypertensive 6R-BH4 and new research describing a promising molecular target for future sepsis therapeutics.
05 Jul 06
Todays Headlines from across the DailyUpdates network (from DailyUpdates 5th July)- Although press releases are quite thin on the ground today because of the July 4th holiday in the US, Abiogen have released important information regarding the start of phase 2 testing of the company's anxiolytic, ABIO 08/01. In addition we feature a review describing a potentially groundbreaking drug delivery technology. This technology harnesses protein transduction domains (PTDs), endogenous peptide sequences
29 Jun 06
The leading pharmaceutical companies have historically focused on developing small molecules to drive their bottom line growth. However, this is set to change, with around 60% of revenue growth for 'Big Pharma' companies forecast to come from biologic products. In fact by 2010, annual sales of biologics will have increased by $26 billion, compared to a $13 billion increase for small molecules.
27 Jun 06
Todays Headlines from across the DailyUpdates network - Today we feature news from Vasogen on their candidate treatment of chronic heart failure plus new data from Johnson & Johnson on a new integrin antagonist that may underly a future treatment of asthma
21 Jun 06
Todays Headlines from across the DailyUpdates network (20th June, 2006): We highlight research from Merck who are developing a novel approach to anxiety and news from ArQule on their oncology candidate
20 Jun 06
Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
19 Jun 06
The US$ 32 bln market of six major protein products is enfacing competition by less costly biogenerics and by improved products via drug delivery or protein engineering technologies and even oral, small molecule solutions
La Merie Business Intelligence